Technology Transfer Partnerships

Technology transfer driver in the Asia-Pacific region

IVI has partnered with six manufacturers from five Asian countries for the technology transfer of new cholera and typhoid vaccines that range from a major industrial Korean conglomerate (SK Chemicals) to a government-affiliated vaccine manufacturer in Vietnam (VaBiotech).

Tech transfer partner Status
VaBiotech, Vietnam Bivalent killed whole-cell oral cholera vaccine

Partnered with VaBiotech on modifying the vaccine and tech-transferred quality control assays and reagents; vaccine currently licensed and used in Vietnam as mORC-VAX.

Shantha Biotechnics, India Bivalent killed whole-cell oral cholera vaccine

Partnered with Shantha on clinical development, licensure in India, and WHO prequalification; Shanchol™ WHO-prequalified in 2011 and currently used in the WHO stockpile.

EuBiologics, South Korea Bivalent killed whole-cell oral cholera vaccine

Currently working with EuBiologics on late-stage clinical development; Euvichol expected to be WHO- prequalified in 2016.

SK Chemicals, South Korea Typhoid conjugate vaccine (Vi -DT)

Currently working with SK Chemicals on clinical development; vaccine expected to be WHO-prequalified by 2020.

PT BioFarma, Indonesia Typhoid conjugate vaccine (Vi-DT)

Currently working with BioFarma on clinical development; vaccine expected to be WHO-prequalified by 2019.

Incepta Vaccine Ltd., Bangladesh Bivalent killed whole-cell oral cholera vaccine
Typhoid conjugate vaccine (Vi- DT)

Currently working with Incepta on clinical development and licensure of the two vaccines for the domestic market.